Are the Protean Effects of Pentoxifylline in the Therapy of Diabetes and Its Complications Still Relevant? David S. H. Bell Review Open access 13 October 2021 Pages: 3025 - 3035
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review Djordje S. PopovicNikolaos PapanasManfredi Rizzo Review Open access 26 October 2021 Pages: 3037 - 3054
Relationship Between Bedside Ketone Levels and Time to Resolution of Diabetic Ketoacidosis: A Retrospective Cohort Study Yoshihiko YuyamaTomoyuki KawamuraTakashi Hamazaki Original Research Open access 09 October 2021 Pages: 3055 - 3066
Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study Wendy LaneMads FaurbyChristophe De Block Original Research Open access 12 October 2021 Pages: 3067 - 3077
Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in China Xinran ZhaoJian MingYingyao Chen Original Research Open access 23 October 2021 Pages: 3079 - 3092
Renal Complications and Duration of Diabetes: An International Comparison in Persons with Type 1 Diabetes Mary DenaAnn-Marie SvenssonMarcus Lind Original Research Open access 25 October 2021 Pages: 3093 - 3105
Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe Andrej JanezTadej BattelinoNataliya Zelinska Original Research Open access 25 October 2021 Pages: 3107 - 3135
Cost-Effectiveness of the FreeStyle Libre® System Versus Blood Glucose Self-Monitoring in Individuals with Type 2 Diabetes on Insulin Treatment in Sweden Johan JendleKatarina Eeg-OlofssonFleur Levrat-Guillen Original Research Open access 25 October 2021 Pages: 3137 - 3152
Performance Evaluation of the Glunovo® Continuous Blood Glucose Monitoring System in Chinese Participants with Diabetes: A Multicenter, Self-Controlled Trial Ran MengTianwei GuDalong Zhu Original Research Open access 26 October 2021 Pages: 3153 - 3165
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes Matthew R. WeirYen-Wen ChenVeronica Ashton Original Research Open access 26 October 2021 Pages: 3167 - 3186
Qualitative and Quantitative Study on Components of Future Time Perspective and Their Association with Persistent Treatment for Type 2 Diabetes Tomoo HidakaNoriko TakahashiTetsuhito Fukushima Original Research Open access 27 October 2021 Pages: 3187 - 3199
Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial Daisuke ItoKazuyuki InoueAkira Shimada Original Research Open access 28 October 2021 Pages: 3201 - 3215
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK Rory J. McCrimmonEdel FallaKaren Palmer Original Research Open access 29 October 2021 Pages: 3217 - 3230
Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy Rory J. McCrimmonMark LamotteElisheva Lew Original Research Open access 29 October 2021 Pages: 3231 - 3241
Challenges in Insulin Therapy for Type 2 Diabetes Israel Hodish Letter Open access 16 October 2021 Pages: 3243 - 3244